Proteo, Inc. (PTEO)
From ValueWiki
Business Description from Pinksheets.com: Proteo Inc. and its wholly owned subsidiary Proteo Biotech AG, a German Corporation, intend to develop, manufacture, promote and market pharmaceuticals and other biotech products. The lead product, Elafin, is a recombinant protein of human origin with anti-inflammatory properties that is under development for the treatment of cardiovascular and pulmonary diseases. Elafin has been successfully tested in a Phase I clinical trial. Proteo, Inc. intends to out-license selected indications and to establish international strategic alliances in order to open up new fields of application and for marketing.[1]
|
|
Company Analysis
- Proteo, Inc. Snapshot[1]
- Outstading Shares: 22,379,350 as of 2006-05-12
- Transfer Agent: Transfer Online, Portland, OR 97204
- Proteo, Inc. Contact Information
- Address: 2102 Business Center Drive Irvine, CA 92612 USA
- Website: http://www.proteo.de
- Phone: 949 253-4616
News Feed
| 11/06/08 9:11 am | PROTEO INC Financials (EDGAR Online Financials) |
| 10/31/08 12:10 pm | PROTEO INC Files SEC form 10-Q, Quarterly Report (EDGAR Online) |
| 08/14/08 3:08 pm | PROTEO INC Files SEC form 10-Q, Quarterly Report (EDGAR Online) |
| 06/11/08 5:06 am | PROTEO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Am (EDGAR Online) |
| 05/20/08 3:05 pm | PROTEO INC Files SEC form 10-Q, Quarterly Report (EDGAR Online) |
| 04/14/08 12:04 pm | PROTEO INC Files SEC form 10KSB, Annual Report (EDGAR Online) |
Leadership
Walter J. Thomsen, CEO/CFO; Dr. Barbara Kahlke, Secretary/CFO
Risks
This section needs content! Click the blue edit link (to the right) to contribute.
Research Links
- Proteo, Inc. Fundamentals
- Proteo, Inc. Technical Analysis
- Proteo, Inc. Message Boards
